Aethlon Medical (AEMD) investor relations material

Opening remarks and agenda

• Meeting commenced at 8:00 A.M. Pacific Time on October 1, 2026, in a virtual format to ensure accessibility for all stockholders.

• Introduction of key company officers and legal counsel, with roles and responsibilities outlined for the meeting.

• The agenda included ten proposals for stockholder consideration, with voting procedures and Q&A protocols explained.

Shareholder proposals

• Election of five directors to serve until the 2027 annual meeting.

• Ratification of Haskell & White LLP as independent auditors for fiscal year ending March 31, 2027.

• Approval of issuance of up to 1,126,602 shares upon warrant exercises from the July 2026 offering.

• Approval of executive compensation as disclosed in the proxy statement.

• Amendment to the 2020 Equity Incentive Plan to increase authorized shares by 100,000.

• Amendment to articles of incorporation to increase authorized common stock from 20 million to 200 million.

• Amendment to authorize 20 million shares of preferred stock and board authority to establish series (not approved).

• Approval for issuance of common stock or convertible securities in future private financings.

• Approval for issuance of common stock in future warrant exercise inducement transactions.

• Approval for adjournment of the meeting if additional proxies were needed.

Overview of voting outcomes

• All director nominees were elected.

• Auditor ratification, warrant share issuance, executive compensation, equity plan amendment, common stock increase, private financing, warrant inducement, and adjournment proposals were approved.

• Proposal to authorize preferred stock and board authority to establish series was not approved.